Skip to main content
Photocure ASA logo

Photocure ASA — Investor Relations & Filings

Ticker · PHO ISIN · NO0010000045 LEI · 5967007LIEEXZXG8OW35 OL Manufacturing
Open in API
Filings indexed 1,333 across all filing types
Latest filing 2010-10-20 Investor Presentation
Country NO Norway
Listing OL PHO

About Photocure ASA

https://www.photocure.com/

Photocure is a specialty pharmaceutical company focused on bladder cancer. It develops and commercializes products and medical devices based on proprietary photodynamic technology. The company's primary offering is Blue Light Cystoscopy (BLC) with its imaging agents, Hexvix®/Cysview®, which is used for the improved detection and management of bladder cancer. Photocure aims to deliver transformative solutions to the urologic oncology community to improve patient outcomes. The company is also engaged in developing advanced diagnostic technologies, including the integration of artificial intelligence with its BLC systems.

Recent filings

Filing Released Lang Actions
Lumacan agreement.pdf (Att: 269007)
Investor Presentation Classification · 90% confidence The document is structured as a slide deck presentation with bullet points, images, and strategic content focused on an exclusive licensing agreement, pipeline overview, milestones, and company strategy. It is not an earnings release, regulatory filing, or annual report but rather a detailed investor-facing presentation describing the deal terms, market rationale, and company objectives. Therefore, it fits the “Investor Presentation” category (Code: IP).
2010-10-20 English
Presentation of the Lumacan agreement
Investor Presentation Classification · 95% confidence The document is very short (565 characters) and explicitly states 'Please find attached todays Lumacan agreement presentation'. According to the 'Menu vs Meal' rule, an announcement stating that a report or presentation is attached or available is classified as a Report Publication Announcement (RPA).
2010-10-20 English
INVITATION OF PRESENTATION OF PHOTOCURE'S AGREEMENT WITH SALIX FOR LUMACAN(TM)
Regulatory Filings Classification · 95% confidence The document is a short announcement (under 1,000 characters) inviting stakeholders to a press and analyst conference regarding a previously announced agreement with Salix Pharmaceuticals. It does not contain the full details of the transaction or the financial report itself, but rather serves as a notification of an upcoming event related to a corporate transaction. Therefore, it is classified as a Regulatory Filing (RNS) as it serves as a general corporate announcement that does not fit into the specific 'Report Publication Announcement' category (which is for the release of documents) or the 'M&A Activity' category (which is for the transaction details themselves).
2010-10-20 English
Photocure signerer avtale med Salix Pharmaceuticals for Lumacan(TM)
Regulatory Filings Classification · 95% confidence The document is a press release announcing a strategic partnership and licensing agreement between Photocure and Salix Pharmaceuticals regarding the development and commercialization of the drug Lumacan. This type of corporate announcement regarding business development, licensing, and strategic partnerships falls under the category of general regulatory announcements or corporate news, which is best classified as RNS (Regulatory Filings) in the absence of a more specific category like M&A (which usually implies full takeovers or mergers).
2010-10-20 Norwegian
Photocure signs agreement with Salix Pharmaceuticals for Lumacan(TM)
M&A Activity Classification · 95% confidence The document is a press release announcing a strategic licensing agreement between Photocure and Salix Pharmaceuticals for the development and commercialization of a product called Lumacan. It details the financial terms (signing fee, milestone payments, royalties) and the nature of the partnership. This type of corporate announcement regarding M&A or strategic licensing/partnership activity falls under the 'M&A Activity' category (TAR).
2010-10-20 English
New publication on Hexvix demonstrating that Hexvix guided fluorescence cystoscopy reduces recurrence in patients with non-muscle invasive bladder cancer
Regulatory Filings Classification · 95% confidence The document is a press release from Photocure announcing the publication of a clinical study in the Journal of Urology regarding their product, Hexvix. It does not fit into financial reporting categories like 10-K, IR, or ER, nor does it represent a corporate governance or management change. As it is a general regulatory announcement regarding company news/product developments that does not fall into the other specific categories, it is classified as a Regulatory Filing (RNS).
2010-10-05 English

Browse filings by year

15 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.